1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
Vitrolife AB

Vitrolife AB

0YAY.IL
Vitrolife ABGB flagInternational Order Book
89.45
SEK
+0.05
- -
12.11BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4.57
5.11
6.65
7.89
9.64
10.61
13.64
11.47
14.67
23.89
25.94
26.65
25.4
26.13
Basic EPS, GAAP
0.57
1.09
1.68
1.75
2.43
2.85
3.53
2.64
2.97
2.91
-28.44
3.79
-37.01
3.36
Free Cash Flow per Basic Share
0.98
1.37
1.57
1.54
2.78
1.56
3.01
3.1
2.8
4.05
4.71
5.21
2.87
4.39
Dividend per Share
0.12
0.2
0.3
0.48
0.53
0.75
0.85
- -
0.77
0.81
0.85
1
1.1
1.1
Book Value per Share
3.17
6.46
7.77
9.38
11.29
13.75
16.53
18.54
113.12
123.56
93.93
100.7
58.28
98.05
Tangible Book Value per Share
1.09
1.29
3.02
3.4
5.69
7.05
9.36
12.07
-16.43
-13.19
-8.72
-6.08
-2.84
-5.39
Basic Weighted Avg Shares
99
100
109
109
109
109
109
109
115
135
135
135
135
135
Sales/Revenue/Turnover
453
511
722
856
1,046
1,151
1,480
1,246
1,681
3,234
3,512
3,609
3,440
3,539
Operating Margin (%)
17.41
26.61
28.87
28.97
32.82
33.79
32.98
30.17
25.46
20.01
21.01
21.95
16.69
19.36
Depreciation Expense
35
23
53
54
67
85
99
84
109
396
425
442
427
121
Net Income, GAAP
56
109
183
190
264
310
383
287
341
394
-3,851
513
-5,012
455
Effective Tax Rate (%)
28.94
25.49
19.17
23.19
22.38
22.05
22.09
21.39
25.22
26.63
- -
23.74
- -
- -
Profit Margin (%)
12.43
21.37
25.31
22.24
25.2
26.9
25.86
23.03
20.29
12.18
-109.65
14.21
-145.7
12.86
Working Capital
88
149
283
317
575
698
948
1,237
453
951
1,357
1,652
1,477
1,542
LT Debt
22
60
36
- -
- -
- -
61
49
2,026
2,043
1,942
1,929
1,562
1,840
Total Equity
316
703
845
1,020
1,229
1,496
1,798
2,017
15,341
16,740
12,723
13,641
7,895
13,282
Return on Invested Capital (%)
15.34
17.12
19.35
18.98
22.93
21.95
22.25
14.83
3.21
2.58
- -
3.95
- -
4.48
Return on Capital (%)
16.14
19.16
21.81
19.49
23
22.68
22.76
14.54
3.47
2.32
- -
3.82
- -
2.99
Return on Common Equity (%)
19.02
21.5
23.68
20.46
23.5
22.78
23.29
15.07
3.93
2.46
-26.15
3.89
-46.55
3.45

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
160
151
153
LT Borrowings
1,837
1,710
1,758
LT Finance Leases
92
90
82
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
135
135
135
Market Capitalization
29,053
21,597
18,834

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
2,357
2,279
2,183
Cash, Cash Equivalents & STI
1,135
1,054
921
Accounts Receivable, Net
648
634
635
Inventories
422
413
430
Total Current Liabilities
705
605
641
Payables & Accruals
- -
- -
- -
ST Debt
160
151
153
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
70.61%
122.16%
-42.12%
Free Cash Flow
17.82%
9.64%
-44.96%
Net Income, GAAP
-217.47%
-446.66%
-1,077%
Sales/Revenue/Turnover
19.75%
26.81%
-4.68%
Total Cash Common Dividend
- -
10.54%
10.37%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
841
941
867
959
3,609
2025
842
871
891
- -
3,440
2026
807
857
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.85
1.06
0.86
1.03
3.79
2025
0.74
0.74
-39.24
- -
-37.01
2026
0.75
0.95
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
1
- -
- -
1
2025
- -
1.1
- -
- -
1.1
2026
- -
1.1
- -
- -
- -

Company Description

APIChatGPT
CEO
Bronwyn Brophy O'Connor
Full Time Employees
1,151
Sector
Healthcare
Industry
Medical - Specialties
Address
Gustaf Werners gata 2 Gothenburg VG Sweden 421 32
IPO Date
Jul 18, 2013
Website
vitrolife.com
Similar Companies
QuidelOrtho Corporation (0A55.L)
United Health Products, Inc. (UEEC)
aap Implantate AG (AAQ1.DE)
Molbio Diagnostics Limited (MOLBIO.NS)
Lumos Diagnostics Holdings Limited (LDX.AX)
Niks Professional Ltd (NPL.SI)
Business
Vitrolife AB is a Sweden-based developer, manufacturer, and provider of advanced life science and reproductive health solutions, specializing in cellular therapies and assisted reproduction technologies. The company focuses on product categories including ART media and equipment; cell culturing and embryo transfer systems; embryo biopsy and vitrification media; sperm preparation and semen analysis tools; diagnostic assays and related consumables; and laboratory automation solutions. Vitrolife operates through multiple brands and product lines designed to support fertility clinics, embryology laboratories, and research institutions. Latest major company changes include recent strategic partnerships and collaborations within the fertility and biotechnology sectors; expansion of product offerings through new ART media formulations and associated consumables; ongoing acquisitions and integrations to broaden portfolio and geographic reach; and organizational refinements to support accelerated product development and market penetration across key regions. Industry context and segments: fertility solutions, assisted reproduction technology, cellular therapy support, laboratory consumables and equipment; target markets include fertility clinics, hospitals, research institutions, and biopharma partners. Geographic footprint spans Europe, North America, Asia-Pacific, and other regions, with headquarters in Gothenburg, Sweden, and founding year dating to the late 20th century. Subsidiaries and parent-company relationships align Vitrolife with a network of affiliated entities delivering global support, distribution, and regulatory compliance.